Par launches authorized generic of Amitiza

Endo's operating company Par is offering the first authorized generic version of Mallinckrodt's Amitiza (lubiprostone) 8-mcg and 24-mcg capsules. The medication is used to treat certain types of constipation, including chronic idiopathic constipation and irritable bowel syndrome with constipation.

"This partnership brings the first Amitiza generic to patients — giving them a cost-effective alternative," said Jon Holden, Endo senior vice president and general manager, generics. "Par is proud to be a reliable, quality supplier that can help bring that choice to patients while expanding our product portfolio."

Amitiza had a market value of approximately $427 million for the 12 months ended Sept. 30, 2020, according to IQVIA.